Towards an individualized management of pubertal induction in girls with hypogonadism: insight into the best replacement outcomes from a large multicentre registry.
cancer survivors
hormone replacement therapy
hypogonadism
oestrogen
progesterone
pubertal induction
puberty
Journal
European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848
Informations de publication
Date de publication:
07 Jun 2023
07 Jun 2023
Historique:
received:
18
01
2023
revised:
08
03
2023
accepted:
05
04
2023
medline:
15
6
2023
pubmed:
26
5
2023
entrez:
26
5
2023
Statut:
ppublish
Résumé
An evidence-based pubertal induction scheme in hypogonadal girls is still to be established. Interestingly, literature data report a suboptimal uterine longitudinal diameter (ULD) in >50% of treated hypogonadal women, negatively influencing their pregnancy outcomes. This study aims to investigate auxological and uterine outcomes of pubertal induction in girls in the light of underlying diagnosis and therapeutic schemes used. Retrospective analysis of longitudinal data from a multicentric registry. Auxological, biochemical, and radiological data were collected at baseline and during follow-up in 95 hypogonadal girls (chronological age > 10.9 years, Tanner stage ≤ 2) treated with transdermal 17β-oestradiol patches for at least 1 year. Induction was started at a median dose of 0.14 mcg/kg/day with a 6-monthly increase and was considered completed for 49/95 patients who started progesterone with a concomitant oestrogen adult dose. At the end of induction, the achievement of the complete breast maturation was associated with a 17β-oestradiol dose at progesterone introduction. ULD showed a significant correlation with a 17β-oestradiol dosage. Final ULD was >65 mm in only 17/45 girls. At multiple regression analysis, pelvic irradiation represented the major determinant of reduced final ULD. After correction for uterine irradiation, ULD was associated with the 17β-oestradiol dose at progesterone introduction. Final ULD was not significantly different from the one assessed after progesterone introduction. Our results provide evidence that progestins, hampering further changes in uterine volume and breast development, should be introduced only in the presence of a concomitant adequate 17β-oestradiol dose and an appropriate clinical response.
Identifiants
pubmed: 37232247
pii: 7180093
doi: 10.1093/ejendo/lvad056
doi:
Substances chimiques
Progesterone
4G7DS2Q64Y
Estradiol
4TI98Z838E
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
467-476Subventions
Organisme : Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Organisme : Italian Ministry of Health, Rome
ID : ICH-NGS 05C202_2012
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Déclaration de conflit d'intérêts
Conflicts of interest: The authors have no conflict of interest to declare.